Overview
Hiroyuki Hirano practices practicing medicine in Wako, Japan.
His clinical expertise encompasses Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Necrosis.
He is actively involved in clinical research, co-authoring 31 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Hiroyuki Hirano
Is Hiroyuki Hirano a top-rated expert for Cutaneous T-Cell Lymphoma (CTCL)?
MediFind is an objective health platform that identifies experts based on real-world data. Hiroyuki Hirano is classified as an Experienced expert for Cutaneous T-Cell Lymphoma (CTCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Hiroyuki Hirano participate in research or clinical trials?
Yes. Hiroyuki Hirano has published 31 articles and abstracts on conditions like Cutaneous T-Cell Lymphoma (CTCL). You can view a list of Hiroyuki Hirano's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Cutaneous T-Cell Lymphoma (CTCL)Mr. Hirano isExperienced. Learn about Cutaneous T-Cell Lymphoma (CTCL).
- NecrosisMr. Hirano isExperienced. Learn about Necrosis.
- T-Cell LymphomaMr. Hirano isExperienced. Learn about T-Cell Lymphoma.